Business Context and Reporting Period
This Form 8-K is filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on July 10, 2019. The company is an emerging growth company incorporated in Delaware with principal executive offices in Carlsbad, California. The filing addresses regulatory compliance issues regarding its listing on the NASDAQ Global Market.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The primary financial metric referenced is the company's failure to meet the NASDAQ Minimum Stockholders' Equity Requirement of $10.0 million.
Material Changes and Compliance Status
- Stockholders' Equity Non-Compliance: On May 15, 2019, the company received notice of non-compliance with NASDAQ Listing Rule 5450(b)(1)(A) due to insufficient stockholders' equity.
- Extension Granted: On July 10, 2019, NASDAQ granted an extension until November 11, 2019, for the company to regain compliance with the equity requirement.
- Minimum Bid Price Non-Compliance: The company remains non-compliant with the Minimum Bid Price Requirement (Rule 5450(a)(1)) as the closing bid price was below $1.00 for 30 consecutive business days. The deadline to regain compliance for this requirement is November 12, 2019.
Outlook, Risks, and Contingencies
Management has submitted a plan to regain compliance but stated there can be no assurance of success. If the company fails to evidence compliance by the November 11, 2019 deadline, it may be subject to delisting. In the event of delisting, the company may appeal the determination to a Listing Qualifications Panel. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of future events and the competitive environment.
Investor Verification Checklist
- Verify the company's current stockholders' equity balance in the most recent 10-Q or 10-K to assess the gap to the $10.0 million requirement.
- Monitor the company's stock price to determine if it meets the $1.00 minimum bid price requirement by November 12, 2019.
- Review the specific details of the compliance plan submitted to NASDAQ on June 28, 2019, to understand the proposed capital raising or restructuring strategy.
- Check for any subsequent filings regarding the outcome of the compliance deadlines in November 2019.